Who this is for
- Clinics using or planning Heidi, Tortus, Accurx Scribe, Dragon DAX, Tandem, Nabla, Otter or similar tools
- Private GP and GP-led clinics
- Specialist clinics
- DPOs, clinical leads, practice managers and boards
Evidence to have ready before routine use
Checklist
- Tool name, use case and clinical workflow documented
- Licence tier confirmed: free, professional or enterprise
- Supplier DPA obtained
- Sub-processor list obtained
- Data residency and hosting position confirmed
- Retention and deletion position confirmed
- Model-training position confirmed
- DPIA screening completed
- DPIA likely required or strongly indicated where high-risk processing indicators apply
- Patient transparency wording agreed
- Objection or dissent route considered where applicable
- Clinician review workflow documented
- AI-generated notes reviewed before entering the patient record
- AI incident route established
- Clinical safety ownership identified
Why this matters
Ambient scribes should not be treated as simple dictation tools. They can introduce evidence questions across data protection, patient transparency, clinical records, human oversight, vendor assurance and incident management. NHS England ambient scribing guidance is primarily NHS-focused, but it provides a useful governance-standard signal for private clinics adopting similar clinical AI workflows.
Common evidence gaps
Indicators ELSA AI often sees in private clinics
- Scribe live before DPIA review
- Vendor evidence held only by one clinician or not held centrally
- Patient explanation is verbal and inconsistent
- No documented human-review workflow
- No incident route for hallucinated or inaccurate notes
- No board-level benefit-risk review
- Clinical safety ownership unclear
What ELSA AI can help produce
The Diagnostic and follow-on work can address these gaps with structured, board-ready outputs.
Outputs include
- Ambient Scribe Assessment Sheet
- DPIA Readiness and Patient Data Exposure Note
- Vendor Data Position and Evidence Tracker
- Patient transparency evidence-gap indicators
- Human oversight and incident-reporting review
- 30-Day Priority Action Plan
The issue is not simply that AI tools exist. The issue is having no documented governance position when someone asks how that AI use is controlled. Clinical AI Exposure Diagnostic™ page explains scope, timeline and fees.
Advisory governance support only. Not legal advice, DPIA sign-off, CQC certification, ICO approval, insurer coverage advice, MDO indemnity advice or clinical safety case sign-off. Final decisions remain with the clinic’s accountable officers and advisers.
Need this evidence mapped for your clinic?
The Clinical AI Exposure Diagnostic™ gives clinic leadership a board-ready view of AI use, patient-data exposure, evidence gaps and priority actions in four working days from completed intake.